404.80
1.23%
+4.8755
Vertex Pharmaceuticals, Inc. stock is currently priced at $404.80, with a 24-hour trading volume of 343.47K.
It has seen a +1.23% increased in the last 24 hours and a -2.60% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $400.8 pivot point. If it approaches the $405.5 resistance level, significant changes may occur.
Vertex Pharmaceuticals, Inc. Stock (VRTX) Financials Data
Vertex Pharmaceuticals, Inc. (VRTX) Revenue 2024
VRTX reported a revenue (TTM) of $9.87 billion for the quarter ending December 31, 2023, a +10.51% rise year-over-year.
Vertex Pharmaceuticals, Inc. (VRTX) Net Income 2024
VRTX net income (TTM) was $3.62 billion for the quarter ending December 31, 2023, a +8.96% increase year-over-year.
Vertex Pharmaceuticals, Inc. (VRTX) Cash Flow 2024
VRTX recorded a free cash flow (TTM) of $3.28 billion for the quarter ending December 31, 2023, a -16.47% decrease year-over-year.
Vertex Pharmaceuticals, Inc. (VRTX) Earnings per Share 2024
VRTX earnings per share (TTM) was $13.89 for the quarter ending December 31, 2023, a +8.26% growth year-over-year.
Vertex Pharmaceuticals, Inc. Stock (VRTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Arbuckle Stuart A | EVP, COO |
Feb 26 '24 |
Sale |
425.70 |
5,034 |
2,142,974 |
49,691 |
ALTSHULER DAVID | EVP, Global Research and CSO |
Feb 26 '24 |
Sale |
425.70 |
4,239 |
1,804,542 |
25,813 |
Sachdev Amit | EVP Chief Patient & Ext Af Off |
Feb 26 '24 |
Sale |
425.70 |
3,004 |
1,278,803 |
55,325 |
Ambrose Kristen | SVP & Chief Accounting Officer |
Feb 26 '24 |
Sale |
425.70 |
883 |
375,893 |
7,965 |
Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. |
Feb 26 '24 |
Sale |
425.70 |
883 |
375,893 |
15,972 |
Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Feb 26 '24 |
Sale |
425.70 |
354 |
150,698 |
55,804 |
Arbuckle Stuart A | EVP, COO |
Feb 21 '24 |
Sale |
421.77 |
3,603 |
1,519,637 |
59,439 |
Sachdev Amit | EVP Chief Patient & Ext Af Off |
Feb 21 '24 |
Sale |
421.77 |
3,191 |
1,345,868 |
60,798 |
ALTSHULER DAVID | EVP, Global Research and CSO |
Feb 21 '24 |
Sale |
421.77 |
3,002 |
1,266,154 |
34,022 |
Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. |
Feb 21 '24 |
Sale |
421.77 |
1,201 |
506,546 |
18,509 |
Vertex Pharmaceuticals, Inc. Stock (VRTX) Latest News
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Zacks Investment Research
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
The Motley Fool
Making Sense of Amazon CEO Andy Jassy's Latest Letter
The Motley Fool
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
The Motley Fool
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
The Motley Fool
About Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):